glatiramer acetate / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
glatiramer acetate / Generic mfg.
LemKids, NCT03368664 / 2016-003100-30: A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT

Active, not recruiting
3
16
Europe, RoW
Alemtuzumab GZ402673, Lemtrada, Glatiramer acetate, Copaxone, Beta-Interferon, Methylprednisolone, Ranitidine, Ceterizine, Dexchlorpheniramine, Paracetamol, Acyclovir, Prednisolone, Diphenydramine, Other H1 antagonist
Genzyme, a Sanofi Company
Multiple Sclerosis
05/21
12/25
2020-004505-32: Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - physician’s choice in the treatment of newly diagnosed relapsing multiple sclerosis (RMS) patients

Ongoing
3
236
Europe
ofatumumab, Glatiramer acetate, Interferon β-1b, Interferon β-1a, Peginterferon β-1a, Teriflunomide, Dimethyl fumarate, OMB157, Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe, Powder and solution for solution for injection, Solution for injection, Solution for infusion in pre-filled syringe, Coated tablet, Gastro-resistant capsule, soft, Kesimpta
Novartis Pharma AG, Novartis Pharma AG
Multiple Sclerosis Sclérose en plaques, Multiple Sclerosis Sclérose en plaques, Diseases [C] - Nervous System Diseases [C10]
 
 
STHENOS, NCT04788615 / 2020-004505-32: Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

Recruiting
3
186
Europe
Ofatumumab, OMB157, First line DMT, Glatiramer acetate or Interferon or Peg-Interferon beta-1a or Teriflunomide or Dimethyl fumarate or Diroximel fumarate
Novartis Pharmaceuticals, Novartis Pharma AG
Multiple Sclerosis
10/25
01/26

Download Options